S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
NASDAQ:IVA

Inventiva (IVA) Stock Forecast, Price & News

$4.20
-0.06 (-1.41%)
(As of 09/29/2023 ET)
Compare
Today's Range
$4.20
▼
$4.29
50-Day Range
$3.41
▼
$4.44
52-Week Range
$2.22
▼
$11.75
Volume
2,118 shs
Average Volume
17,876 shs
Market Capitalization
$217.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.33
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Inventiva MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
360.3% Upside
$19.33 Price Target
Short Interest
Healthy
0.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Inventiva in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.02) to ($2.15) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

432nd out of 972 stocks

Pharmaceutical Preparations Industry

191st out of 449 stocks

See Top Rated MarketRank™ Stocks Here

IVA stock logo

About Inventiva (NASDAQ:IVA) Stock

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Price History

IVA Stock News Headlines

September 28, 2023 | finanznachrichten.de
INVENTIVA: Inventiva reports its 2023 first-half financial results and provides a corporate update
September 28, 2023 | finance.yahoo.com
Inventiva reports its 2023 first-half financial results and provides a corporate update
October 1, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
September 26, 2023 | americanbankingnews.com
Inventiva (IVA) to Release Earnings on Thursday
September 23, 2023 | americanbankingnews.com
Inventiva's (IVA) "Buy" Rating Reaffirmed at Roth Mkm
September 21, 2023 | markets.businessinsider.com
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
September 21, 2023 | markets.businessinsider.com
Pre-market Movers: MURF, IFRX, NEPT, UPTD, AEHL…
September 20, 2023 | marketwatch.com
Inventiva ADRs Rise 9% Following Licensing Deal
October 1, 2023 | Behind the Markets (Ad)
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
September 20, 2023 | finance.yahoo.com
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
September 20, 2023 | finance.yahoo.com
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
September 12, 2023 | msn.com
Industry slow to embrace new fatty liver disease nomenclature
August 31, 2023 | msn.com
urban-gro announces sale of investment for proceeds of $2.3 million
August 31, 2023 | msn.com
Inventiva announced €35.7M funding, eyes future raise to meet obligations
August 31, 2023 | finance.yahoo.com
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
August 14, 2023 | msn.com
Drugmakers still chasing potentially lucrative NASH market, despite setbacks
July 28, 2023 | finanznachrichten.de
INVENTIVA: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
July 28, 2023 | finance.yahoo.com
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
July 28, 2023 | finance.yahoo.com
Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
July 28, 2023 | finance.yahoo.com
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
June 24, 2023 | finance.yahoo.com
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
June 16, 2023 | benzinga.com
HC Wainwright & Co. Reiterates Buy on Inventiva, Maintains $35 Price Target
June 16, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Inventiva (IVA)
June 16, 2023 | markets.businessinsider.com
Where Inventiva Stands With Analysts
June 14, 2023 | msn.com
Inventiva jumps 25% after mid-stage data for NASH candidate
June 14, 2023 | markets.businessinsider.com
Inventiva Rises In Morning Trade
June 14, 2023 | msn.com
Inventiva Soars on Promising Phase 2 Data in Fatty Liver Disease
See More Headlines
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

IVA Company Calendar

Today
10/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IVA
CUSIP
N/A
CIK
1756594
Web
www.inventivapharma.com
Phone
33-3-80-44-75-00
Fax
N/A
Employees
109
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$19.33
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+360.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.63
Current Ratio
3.47
Quick Ratio
3.45

Sales & Book Value

Annual Sales
$12.83 million
Price / Sales
16.94
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.14 per share
Price / Book
3.68

Miscellaneous

Outstanding Shares
51,750,000
Free Float
35,192,000
Market Cap
$217.35 million
Optionable
Not Optionable
Beta
0.99

Social Links

5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Frederic Cren (Age 57)
    Co-Founder, CEO & Chairman
    Comp: $539.62k
  • Dr. Pierre Broqua Ph.D. (Age 61)
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
    Comp: $404.75k
  • Mr. Jean Volatier (Age 58)
    Chief Financial Officer
  • Alice Roudot-Ketelers Pharm.D.
    Chief Operating Officer
  • Mr. Eric Duranson L.L.M. (Age 49)
    Gen. Counsel
  • Ms. Nathalie Harroy (Age 56)
    Head of HR
  • Dr. Irena Konstantinova
    Head of Biology & Pharmacology
  • Dr. Michael Cooreman (Age 65)
    Chief Medical Officer
  • Mr. Jean-Paul Dutertre M.D.
    Head of Pharmacovigilance

Key Competitors

View All Competitors













IVA Stock - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IVA shares.
View IVA analyst ratings or view top-rated stocks.

What is Inventiva's stock price forecast for 2023?

5 equities research analysts have issued twelve-month price targets for Inventiva's stock. Their IVA share price forecasts range from $11.00 to $35.00. On average, they expect the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 360.3% from the stock's current price.
View analysts price targets for IVA or view top-rated stocks among Wall Street analysts.

How have IVA shares performed in 2023?

Inventiva's stock was trading at $4.46 at the beginning of the year. Since then, IVA shares have decreased by 5.8% and is now trading at $4.20.
View the best growth stocks for 2023 here.

Are investors shorting Inventiva?

Inventiva saw a decline in short interest in September. As of September 15th, there was short interest totaling 90,900 shares, a decline of 5.6% from the August 31st total of 96,300 shares. Based on an average daily volume of 25,200 shares, the days-to-cover ratio is currently 3.6 days.
View Inventiva's Short Interest.

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

What is Inventiva's stock symbol?

Inventiva trades on the NASDAQ under the ticker symbol "IVA."

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inventiva's stock price today?

One share of IVA stock can currently be purchased for approximately $4.20.

How much money does Inventiva make?

Inventiva (NASDAQ:IVA) has a market capitalization of $217.35 million and generates $12.83 million in revenue each year.

How many employees does Inventiva have?

The company employs 109 workers across the globe.

How can I contact Inventiva?

Inventiva's mailing address is 50 RUE DE DIJON, DAIX I0, 21121. The official website for the company is www.inventivapharma.com. The company can be reached via phone at 33-3-80-44-75-00 or via email at finance@inventivapharma.com.

This page (NASDAQ:IVA) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -